Key result
Variant ATTR-CM linked to similar 40-month survival as wild-type under tafamidis therapy.
Why the study?
Does tafamidis treatment result in different mortality and hospitalization outcomes in variant versus wild-type ATTR-CM?
Population
352 patients with transthyretin amyloid cardiomyopathy, median age ~73, predominantly male. Patients with…
Comparison
Tafamidis in patients with variant ATTR-CM vs Tafamidis in patients with wild-type ATTR-CM
Design
Cohort
Follow-up
up to 40 months
Authors
Loading...
In a real-world matched cohort, tafamidis provided benefits for both variant and wild-type ATTR-CM, though patients with the wild-type genotype demonstrated slightly better survival and hospitalization outcomes.
Cohort (n=352)
Does tafamidis treatment result in different mortality and hospitalization outcomes in variant versus wild-type ATTR-CM?
Absolute Event Rate: 61.3% vs 65.8%
In a real-world matched cohort, tafamidis provided benefits for both variant and wild-type ATTR-CM, though patients with the wild-type genotype demonstrated slightly better survival and hospitalization outcomes.
Maurer et al. (2025) conducted a cohort in Variant and wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) (n=352). Variant ATTR-CM genotype vs. Wild-type ATTR-CM genotype was evaluated on All-cause mortality (ACM) survival probability at 40 months. Among patients with ATTR-CM treated with tafamidis, those with the variant genotype had a 40-month survival probability of 61.3% compared to 65.8% for those with the wild-type genotype.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: